Atara Biotherapeutics Inc (NASDAQ: ATRA) is 40.41% higher on its value in year-to-date trading and has touched a low of $0.20 and a high of $3.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ATRA stock was last observed hovering at around $0.68 in the last trading session, with the day’s gains setting it 0.04%.
Currently trading at $0.72, the stock is 0.32% and -1.91% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing 5.45% at the moment leaves the stock -41.37% off its SMA200. ATRA registered -75.84% loss for a year compared to 6-month loss of -54.43%. The firm has a 50-day simple moving average (SMA 50) of $7.29 and a 200-day simple moving average (SMA200) of -$0.10.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.33% gain in the last 1 month and extending the period to 3 months gives it a 25.76%, and is 7.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.53% over the week and 11.59% over the month.
Atara Biotherapeutics Inc (ATRA) has around 334 employees, a market worth around $93.02M and $4.54M in sales. Distance from 52-week low is 262.54% and -77.29% from its 52-week high.
Atara Biotherapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.48 with sales reaching $11.55M over the same period.The EPS is expected to shrink by -7.41% this year, but quarterly earnings will post -75.70% year-over-year. Quarterly sales are estimated to grow 5,126.20% in year-over-year returns.
132 institutions hold shares in Atara Biotherapeutics Inc (ATRA), with institutional investors hold 72.16% of the company’s shares. The shares outstanding are 129.19M, and float is at 119.97M with Short Float at 8.46%. Institutions hold 67.58% of the Float.
The top institutional shareholder in the company is Baupost Group, Inc,.(The) LLC with over 9.77 million shares valued at $15.74 million. The investor’s holdings represent 9.67% of the ATRA Shares outstanding. As of Jun 29, 2023, the second largest holder is Wasatch Advisors LP with 8.28 million shares valued at $13.34 million to account for 8.19% of the shares outstanding. The other top investors are Blackrock Inc. which holds 8.26 million shares representing 8.17% and valued at over $13.3 million, while JP Morgan Chase & Company holds 7.64% of the shares totaling 7.72 million with a market value of $12.43 million.
Atara Biotherapeutics Inc (ATRA) Insider Activity
The most recent transaction is an insider sale by Touchon Pascal, the company’s President and CEO. SEC filings show that Touchon Pascal sold 24,844 shares of the company’s common stock on Mar 04 ’24 at a price of $0.72 per share for a total of $17888.0. Following the sale, the insider now owns 1.91 million shares.
Atara Biotherapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Nguyen AnhCo (EVP, Chief Sci. & Tech Officer) sold a total of 10,746 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $0.72 per share for $7737.0. Following the transaction, the insider now directly holds 0.94 million shares of the ATRA stock.
Still, SEC filings show that on Mar 04 ’24, Murugan Amar (EVP, Chief Legal Officer) disposed off 10,044 shares at an average price of $0.72 for $7232.0. The insider now directly holds 727,521 shares of Atara Biotherapeutics Inc (ATRA).
